Inicio・Lista de Acciones・Denali Therapeutics Inc

Denali Therapeutics Inc

Cerrado

SectorSanidad

20.34 -3.37

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

20.91

Máximo

21.56

Métricas clave
By Trading Economics
Ingresos	894K -128M
Ventas	3.6M 3.6M
BPA	-0.68
Margen de beneficios	-3,539.206
Empleados	503
EBITDA	1.6M -124M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+70.33% upside

Dividendos
By Acuity
Próximas Ganancias	4 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-113M 3.6B
Apertura anterior	23.71
Cierre anterior	20.34

Denali Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2026, 19:36 UTC

Social Media

Denali Therapeutics Inc's shares are lower today, following a recent low of -2.15%. The stock remains below its 20-day moving average.

3 sept 2026, 19:36 UTC

Denali Therapeutics Inc. shares are lower today, continuing a six-session decline amid no specific news. Earlier, the stock peaked before declining.

28 ago 2026, 20:08 UTC

Denali Therapeutics shares are lower today, reflecting broader market trends amid rising U.S. Treasury yields and inflation concerns. The stock remains below its 20-day moving average.

25 ago 2026, 20:07 UTC

News

B. Riley analyst raised Denali Therapeutics Inc's price target to $30.00 while maintaining a Buy rating, coinciding with shares advancing since Monday's close.

24 ago 2026, 22:46 UTC

Denali Therapeutics Inc's shares are higher in after-market trading, reflecting a cumulative gain since Monday's close. No specific news was identified for this movement.

20 ago 2026, 19:16 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today, reflecting broader market trends. The stock has declined since Wednesday amid volatility in biotech and small-cap indices.

19 ago 2026, 20:02 UTC

Correlated Moves

DNLI is higher Wednesday, recovering with the SPDR S&P Biotech ETF.

17 ago 2026, 19:36 UTC

Correlated Moves

Denali Therapeutics Inc is trading higher today, supported by gains in the biotechnology sector. The stock remains near its 20-day moving average.

13 ago 2026, 19:36 UTC

News

Denali Therapeutics reported Q2 revenue of $3.6 million from AVLAYAH, but shares are lower despite expectations for growth in Q3.

12 ago 2026, 19:36 UTC

Denali Therapeutics Inc. shares are higher Wednesday, buoyed by positive market sentiment following a modest rise in the core Consumer Price Index.

11 ago 2026, 23:21 UTC

Denali Therapeutics Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

10 ago 2026, 19:36 UTC

Correlated Moves

Denali Therapeutics Inc shares declined during Monday's session, tracking broader market trends as the Russell 2000 Index fell. Energy market volatility also influenced the move.

7 ago 2026, 19:26 UTC

Social Media

News

Denali Therapeutics shares are lower after a $127.6 million net loss in Q2, missing revenue expectations despite a price target increase from UBS to $34.

6 ago 2026, 21:03 UTC

News

Denali Therapeutics shares rise in after-market hours following strong revenue from AVLAYAH and plans to advance Alzheimer's programs despite an EPS miss.

3 ago 2026, 19:46 UTC

Correlated Moves

News

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

31 jul 2026, 20:02 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

30 jul 2026, 19:18 UTC

Correlated Moves

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

29 jul 2026, 22:01 UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

28 jul 2026, 18:46 UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

27 jul 2026, 19:56 UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

24 jul 2026, 19:26 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

22 jul 2026, 17:46 UTC

Correlated Moves

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

21 jul 2026, 17:36 UTC

Correlated Moves

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

20 jul 2026, 23:41 UTC

Correlated Moves

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.

Comparación entre iguales

Cambio de precio

Denali Therapeutics Inc previsión

Precio Objetivo

By TipRanks

70.33% repunte

Estimación a 12 Meses

Media 35.923 USD 70.33%

Máximo 42 USD

Mínimo 26 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Denali Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Denali Therapeutics Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.